United Kingdom Archives

News and Trends 26 Oct 2015

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

Biotech financing beats record over record since beginning of 2014. Financing has never been as high in Europe (though of course, we know this has always been the case for the US). Just look at Neil Woodford, famous british investor who raised €1.1Bn for its fund and injected it in many companies like Immuncore (2nd biggest VC round […]

October 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 21 Oct 2015

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

Gritstone Pharmaceuticals is a US start-up which will focus on R&D of its new CAR-T cancer therapy technique: tumor-specific neo-antigen (TSNA). An impressive financial syndicate is backing its launch this month, having achieved a £102M series A pot for their lung cancer research. This cash is a clear indication that this start-up has the 3 […]

October 21, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease. Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Oct 2015

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is developed for a much more specific immunohistochemical alternative to the traditional Rodent equivalents. Now the most recent generation of mAbs from this platoform is able to detect PD-L1 tumor proteins for immuno-oncology research. The conventional […]

October 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Oct 2015

Nobel Prize in Chemistry 2015: DNA Repairing Mechanisms that Keep you Alive

DNA repair mechanisms are crucial to our existence. Without them, we would not survive because of DNA damage caused by the environment (e.g UV light damage, radiation etc.). This crucial research into discovery of three DNA repair mechanisms was led by Thomas Lindahl, Paul Modrich and Aziz Sancar who jointly received this years Nobel Prize […]

October 7, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 7 Oct 2015

Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize!

The first paper on CRISPR gene editing tech was only published in 2012. As a key player in the biotech revolution, CRISPR is the discovery of the century, permitting a whole new field of gene-editing for therapeutic purposes in a range of different research areas. Two of those responsible for the existence of CRISPR-Cas9, Jennifer […]

October 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Oct 2015

Ancient Microalgae hold the Crucial gene needed for the Evolution of Plants to Land

Microalgae proves to possibly be the oldest organism exploited by the Biotech industry. Now a mass research collaboration from Wisconsin (US), Cologne (Germany), Toulouse (France) and Norwich (UK) amongst others have published in PNAS that the microalgal genes needed for bacterial and fungal symbiosis were originally present before the transition of ancient plants to land. […]

October 6, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 2 Oct 2015

BBSRC: Profile of a UK Biosciences Research Council

A brief profile of The Biotechnology and Biological Sciences Research Council (BBSRC). The BBSRC is the largest UK research council for non-medical biosciences, looking to dominate market in promoting public dialogue on bioscience and funding curiosity-led research, through a direct investment in bioscience research in UK universities and institutes. In particular BBSRC is aiming at promoting […]

October 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 1 Oct 2015

Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government

The “Berg Interrogative Biology” program from Boston (US) is a form of artificial intelligence the UK government has employed to work its Genome project. The platform will use a combination of systems biology techniques to analyse up to 100,000 genomes sourced from England’s National Health Service (NHS) for Genomics England (owned by the UK Department […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma

As we already well know, Neil Woodford is an Economist investor listed as one of the most influential figures in the European biotech industry. From London (UK), his private equity firm Woodford Patient Capital Trust is now planning to dish out €25M to AMO Pharma, to further their phase II pipeline therapies for CNS disorders such […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Nobel Prize in Chemistry 2015: DNA Repairing Mechanisms that Keep you Alive

Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize!

Ancient Microalgae hold the Crucial gene needed for the Evolution of Plants to Land

BBSRC: Profile of a UK Biosciences Research Council

Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!